



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 12 2002

In re application of: Moore et al.

Application Serial No.: 09/376,430

Art Unit: 1646

Filed: August 18, 1999

Examiner: O'Hara, E.

TECH CENTER 1600/2900

For: **Cytokine Receptor Common
Gamma Chain Like**

Attorney Docket No.: PF466P1

30/D
JGJ
9/16/02

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111 TO PAPER NO. 26

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated 9 April 2002, (Paper No. 26), Applicants hereby request that the following amendments and remarks be entered into the above-identified application. Submitted concurrently herewith is: (a) a Fee Transmittal; (b) a request for an extension of time of 2 months up to and including September 9, 2002; and (c) the Declarations of Paul A. Moore and Thi-Sau Migone Under 37 C.F.R. § 1.132; (d) Exhibits A-G; and (e) Version With Markings to Show Changes Made. Please amend the application as follows.

In the Claims:

Please amend the claims as follows:

40. (Twice Amended) An isolated polypeptide having immune cell proliferative activity comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence comprising residues m to 371 of SEQ ID NO:2, where m is an integer in the range of +2 to +370; and

(b) an amino acid sequence comprising residues 1 to n of SEQ ID NO:2, where n is an integer in the range of +2 to +371,

wherein said amino acid sequence comprises at least seven contiguous amino acid residues of SEQ ID NO:2.